Filing Flows › Adma Biologics (ADMA) › Free cash flow
Adma Biologics (ADMA) free cash flow by quarter
Adma Biologics' free cash flow was $15.4M in Q3 2026 (third quarter 2026), -44% from Q2 2026. Over the last 5 quarters it ranged from $15.4M (Q3 2026) to $55.7M (Q1 2026).
| Quarter | Free cash flow | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $15.4M | -44% | — |
| Q2 2026 | $27.3M | -51% | +46% |
| Q1 2026 | $55.7M | +61% | — |
| Q4 2025 | $34.6M | +85% | — |
| Q2 2025 | $18.7M | — | — |
Q3 2026 at a glance
Adma Biologics, Q3 2026: revenue $141M (+5% year over year), operating margin 48.0%, net earnings $49.9M, operating cash flow $17.4M. The chart follows the revenue to costs, profit and cash.
Questions
What is Adma Biologics' free cash flow?
Adma Biologics' free cash flow was $15.4M in Q3 2026 (third quarter 2026), -44% from Q2 2026.
How has Adma Biologics' free cash flow changed?
Over the last 5 quarters it ranged from $15.4M (Q3 2026) to $55.7M (Q1 2026).